RSVI-302

N/A

Report date: 2023/07/28 17:06:23

Base Information

Drug NameRSVI-302
Drug Alias NameRSVI-302
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNA
Mechanisms of ActionRNA interferenceKruppel-like transcription factors inhibitors
TargetsKruppel-like transcription factors
Therapy Area/IndicationsObesityDiabetes MellitusMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRosVivo Therapeutics IncUniversity of Nevada Reno
China Registration ClassN/A

Develop Information

Active CompaniesRosVivo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsObesityDiabetes MellitusMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A